Velez MG, Kosiorek HE, Egan JB, et al. - With the aim to determine the effects of altered tumor suppressor genes (TSG-alt) on outcomes in metastatic, hormone-sensitive prostate cancer (M1-HSPC), researchers retrieved data of patients with M1-HSPC at their institution who underwent treatment with first-line androgen deprivation therapy plus docetaxel (ADT + D) or abiraterone acetate (ADT + A). In addition, they examined the prognostic impact of these genes by first-line treatment. Of 97 identified patients with M1-HSPC: 48 (49%) were treated with ADT + A and 49 (51%) with ADT + D. Findings suggest superior predictive value of the presence of TSG-alt over clinical criteria for early progression during first-line treatment of M1-HSPC. Less effectiveness was recorded for ADT + A in patients with vs without TSG-alt. When confirmed, these findings may establish the necessity for inclusion of molecular stratification in treatment algorithms.